Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 12/20 | 0.80 |
| ▸ | MAPK10 | P53779 | 7/20 | 0.70 |
| ▸ | MAPK9 | P45984 | 6/20 | 0.70 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.70 |
| ▸ | CDC7 | O00311 | 1/20 | 0.70 |
| ▸ | PLK4 | O00444 | 1/20 | 0.70 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.70 |
| ▸ | AURKA | O14965 | 1/20 | 0.70 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.70 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.70 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.70 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.70 |
| ▸ | JAK2 | O60674 | 1/20 | 0.70 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.70 |
| ▸ | PAK4 | O96013 | 1/20 | 0.70 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.70 |
| ▸ | EGFR | P00533 | 1/20 | 0.70 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.70 |
| ▸ | PRKCG | P05129 | 1/20 | 0.70 |
| ▸ | INSR | P06213 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13395462 | 0.91 | PTK2 (0.84) | PTK2MAPK10MAPK9MAPK8CDC7 | |
| SCHEMBL2825624 | 0.89 | PTK2 (1.00) | PTK2MAPK10MAPK9MAPK8CDC7 | |
| SCHEMBL13395466 | 0.84 | POLB (0.63) | PTK2MAPK8EGFRINSRIGF1R | |
| SCHEMBL14503208 | 0.83 | MAPT (0.69) | PTK2MAPK8INSRMAPK1LRRK2 | |
| SCHEMBL24377553 | 0.83 | PTK2 (1.00) | PTK2MAPK10MAPK9MAPK8CDC7 | |
| SCHEMBL29378728 | 0.83 | PTK2 (1.00) | PTK2MAPK10MAPK9MAPK8CDC7 | |
| SCHEMBL19654204 | 0.83 | PTK2 (0.85) | PTK2MAPK10MAPK9MAPK8CDC7 | |
| SCHEMBL375524 | 0.83 | PTK2 (1.00) | PTK2MAPK10MAPK9MAPK8CDC7 | |
| SCHEMBL29730430 | 0.83 | PTK2 (1.00) | PTK2MAPK10MAPK9MAPK8CDC7 | |
| SCHEMBL12627645 | 0.82 | PTK2 (0.84) | PTK2MAPK10MAPK9MAPK8CDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130096100-A1 | DI(ARYLAMINO)ARYL COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-04-18 | — | — | US | disclosed |
| US-20130096100-A1 | DI(ARYLAMINO)ARYL COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-04-18 | — | — | US | disclosed |
| US-8318702-B2 | Di(arylamino)aryl compounds | ASTELLAS PHARMA INC. (JP) | 2012-11-27 | — | — | US | disclosed |
| US-8318702-B2 | Di(arylamino)aryl compounds | ASTELLAS PHARMA INC. (JP) | 2012-11-27 | — | — | US | disclosed |
| US-8318702-B2 | Di(arylamino)aryl compounds | ASTELLAS PHARMA INC. (JP) | 2012-11-27 | — | — | US | disclosed |
| US-20100099658-A1 | DI(ARYLAMINO)ARYL COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20100099658-A1 | DI(ARYLAMINO)ARYL COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20100099658-A1 | DI(ARYLAMINO)ARYL COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-22 | — | — | US | disclosed |
| EP-2172461-A1 | DI(ARYLAMINO)ARYL COMPOUND | Astellas Pharma Inc. (JP) | 2010-04-07 | — | — | EP | disclosed |
| EP-2172461-A1 | DI(ARYLAMINO)ARYL COMPOUND | Astellas Pharma Inc. (JP) | 2010-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096100-A1 | DI(ARYLAMINO)ARYL COMPOUND | ERBB4, EGFR, ALK | PTK2 375/4885MAPK10 1100/4885MAPK9 353/4885 |
| US-20100099658-A1 | DI(ARYLAMINO)ARYL COMPOUND | ERBB4, EGFR, ALK | PTK2 375/4885MAPK10 1100/4885MAPK9 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.